Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | Day Return | YTD Return |
|---|---|---|---|
| All Industries | 100% | 0.11% | 0.88% |
| Drug Manufacturers - General | 33.99% | -0.46% | 6.19% |
| Healthcare Plans | 13.18% | 3.21% | -7.31% |
| Medical Devices | 13.17% | 0.24% | 4.56% |
| Diagnostics & Research | 11.31% | -0.61% | -0.10% |
| Biotechnology | 11.17% | -0.85% | -8.18% |
| Medical Instruments & Supplies | 6.73% | -0.45% | 2.46% |
| Medical Care Facilities | 2.91% | -1.76% | 8.15% |
| Drug Manufacturers - Specialty & Generic | 2.67% | 1.77% | -9.95% |
| Medical Distribution | 2.46% | 1.18% | 10.68% |
| Health Information Services | 2.17% | -0.05% | 7.83% |
| Pharmaceutical Retailers | 0.24% | -0.03% | -32.05% |
All Industries
-
Note: Percentage % data on heatmap indicates Day Return
Largest Companies in This Sector
Name | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 746.74 | 826.53 | 11.35% | Buy | ||||
| 468.89 | 576.19 | 6.91% | Buy | ||||
| 144.45 | 176.17 | 5.57% | Buy | ||||
| 125.06 | 137.02 | 5.07% | Buy | ||||
| 162.54 | 184.49 | 4.60% | Buy | ||||
| 554.55 | 605.43 | 3.38% | Buy | ||||
| 109.21 | 126.74 | 3.03% | Buy | ||||
| 240.34 | 264.26 | 2.85% | Buy | ||||
| 25.69 | 31.10 | 2.33% | Buy | ||||
| 265.64 | 307.50 | 2.28% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
Name | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 138.68 | 41.319B | 0.09% | ||
| 253.81 | 21.195B | 0.10% | ||
| 126.97 | 7.632B | 0.45% | ||
| 85.61 | 7.551B | 0.35% | ||
| 55.56 | 5.76B | 0.40% |
Mutual Fund Opportunities
Name | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 202.33 | 47.432B | 0.34% | ||
| 85.31 | 47.432B | 0.34% | ||
| 126.89 | 21.195B | 0.10% | ||
| 89.38 | 15.399B | 0.80% | ||
| 89.63 | 14.712B | 0.80% |
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
Analyst Report: The Cooper Companies, Inc.
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
RatingNeutralPrice TargetAnalyst Report: Laboratory Corporation of America Holdings
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
RatingBullishPrice TargetAnalyst Report: Integra Lifesciences Hldgs Cor
Based in Princeton, New Jersey, Integra is a medical device company that develops and markets devices for use in neurosurgery, nerve repair, and skin and wound repair. The company's products are used in cranial and spinal procedures, peripheral nerve repair, the repair of skin and deeper tissue from burns and vehicular accidents, and the repair and reconstruction of soft tissue. The company has two segments: Codman Specialty Surgical and Tissue Technologies. It also sells products through private-label relationships with other medical device companies.
RatingNeutralPrice TargetMarket Update: BAC, IART, MS, SCHW, SWX
Stocks were mixed on Tuesday morning as investors digested earning reports. Starts of residential units fell to a seasonally adjusted annual rate of 1,321,000 in March, a 14.7% decline from February's revised rate and well short of expectations. Building permits issued also slipped to an annualized 1,458,000, a 4.3% decline from February and also short of expectations. Housing starts declined in all regions with the exception of the West, which rose 7.1%. Building permits issued were flat for units of five or more homes per building, while declining 10.3% for buildings of two to four units, and 5.7% for single-family homes. Regionally, permits issued fell in the Northeast (-20.8%), Midwest (-14.7%), and South (-0.6%), while growing in the West (+5.1%). The Dow was up 0.4%, while the S&P 500 was flat and the Nasdaq rose 0.1%. Crude oil is trading near above $85 per barrel and gold rose $22 to $2405 per ounce.

